Latest Clarity Pharmaceuticals (ASX:CU6) News
Page 4
Page 4 of 5
Clarity Pharmaceuticals Advances Prostate Cancer Trials with $226M Cash Buffer
30 Jan 2026
Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026
18 Jan 2026
Clarity Pharmaceuticals Advances SECuRE Trial with Promising Prostate Cancer Results
15 Jan 2026
Clarity’s Cu-SAR-bisPSMA Shows Superior Prostate Cancer Detection Ahead of EAU 2026
24 Dec 2025
Clarity Pharmaceuticals Advances Cu-64 SARTATE to Pivotal Phase III Trial After FDA Nod
22 Dec 2025
Clarity Pharmaceuticals Secures $203M to Advance Copper-Based Cancer Therapies
25 Nov 2025
Clarity Pharmaceuticals Secures $203M, Advances Prostate Cancer Imaging and Therapy
31 Oct 2025
Clarity Pharmaceuticals Clarifies SAR-bisFAP Data Timing Amid Share Surge
27 Oct 2025
Clarity Pharmaceuticals Secures Key Copper-67 Supply for Prostate Cancer Trials
16 Oct 2025
Clarity’s Cu-SAR-bisPSMA Outperforms Standard Imaging in Prostate Cancer Trial
14 Oct 2025
Clarity Pharmaceuticals Secures $203M, Advances Copper Theranostics in Cancer Trials
31 July 2025